You are currently viewing a new version of our website. To view the old version click .
Medical Sciences Forum
  • Abstract
  • Open Access

18 August 2022

In Vitro Inhibitory Effects on Pancreatic Lipase and α-Glucosidase Activity by Extracts and Fractions of Lavandula angustifolia L. from Southern Italy †

,
and
Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy
*
Author to whom correspondence should be addressed.
Presented at the 8th International Electronic Conference on Medicinal Chemistry, 1–30 November 2022; Available online: https://ecmc2022.sciforum.net/.
This article belongs to the Proceedings The 8th International Electronic Conference on Medicinal Chemistry

Abstract

Lavandula angustifolia is one of the most popular medicinal plants, and is a rich source of bioactive compounds. Most of the studies on lavender have focused on its essential oil and its use as a sleep aid, calmative, fragrant, insect repellant and flavoring agent. This work is aimed at investigating, for the first time, the potential role of L. angustifolia in the management of metabolic syndrome (MetS), one of the major and escalating public-health and clinical challenges worldwide. Herein, the aerial parts of L. angustifolia, collected in June 2021 in the “Parco Nazionale del Pollino”, Southern Italy, were subjected to extraction by maceration with ethanol. Then, the total extract was partitioned with solvents at different polarities such as n-hexane, dichloromethane and ethyl acetate. The extract and fractions were evaluated for their ability to inhibit alpha-glucosidase as well as lipase. The ethanol extract remarkably inhibited α-glucosidase and lipase (IC50 of 2.55 and 30.50 μg/mL, respectively) better than the positive control acarbose and orlistat (IC50 of 35.51 and 37.12 μg/mL, respectively). The most active fraction was dichloromethane with an IC50 of 14.67 and 17.64 μg/mL, against α-glucosidase and lipase, respectively. Taking into account the obtained results, L. angustifolia could be used for the formulation of new products; however, further preclinical studies will be needed to confirm its in vivo efficacy, as well as to prove the safety of the tested extracts and fractions.

Supplementary Materials

The presentation material of this work is available online at https://www.mdpi.com/article/10.3390/ECMC2022-12874/s1.

Author Contributions

Conceptualization, R.T., M.R.L. and A.R.C.; investigation, R.T., M.R.L. and A.R.C.; data curation, R.T., M.R.L. and A.R.C.; writing—original draft preparation, R.T.; writing—review and editing, R.T., M.R.L., A.R.C.; supervision, R.T.; funding acquisition, R.T. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by Calabria Region (Italy) through the project titled “Aumento della produttività e della qualità di colture fuori suolo (CENTOZAF)” (CUP-J16G20000480005) within the framework PSR Calabria 14/20 Misura 16.02.01 “Sviluppo di nuovi prodotti, pratiche, processi e tecnologie nel settore agroalimentare e forestale”-Partnership: Azienda Agricola Grisolia Antonio, Azienda Agricola Armentano Francesco, and Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Italy.

Institutional Review Board Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.